WO2004026319A3 - Compositions pharmaceutiques utilisees pour le traitement de cancers - Google Patents

Compositions pharmaceutiques utilisees pour le traitement de cancers Download PDF

Info

Publication number
WO2004026319A3
WO2004026319A3 PCT/EP2003/010280 EP0310280W WO2004026319A3 WO 2004026319 A3 WO2004026319 A3 WO 2004026319A3 EP 0310280 W EP0310280 W EP 0310280W WO 2004026319 A3 WO2004026319 A3 WO 2004026319A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancers
treatment
useful
pharmaceutical compositions
increasing camp
Prior art date
Application number
PCT/EP2003/010280
Other languages
English (en)
Other versions
WO2004026319A2 (fr
Inventor
The Hugues De
Marie-Claude Guillemin-Debons
Michel Lanotte
Laurent Degos
Original Assignee
Centre Nat Rech Scient
Inst Nat Sante Rech Med
The Hugues De
Marie-Claude Guillemin-Debons
Michel Lanotte
Laurent Degos
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Nat Rech Scient, Inst Nat Sante Rech Med, The Hugues De, Marie-Claude Guillemin-Debons, Michel Lanotte, Laurent Degos filed Critical Centre Nat Rech Scient
Priority to AU2003270202A priority Critical patent/AU2003270202A1/en
Publication of WO2004026319A2 publication Critical patent/WO2004026319A2/fr
Publication of WO2004026319A3 publication Critical patent/WO2004026319A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/285—Arsenic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne l'utilisation d'au moins une substance pouvant augmenter le teneur en cellules de cAMP ou de ses dérivés, relativement à la teneur initiale en cellules de cAMP ou de ses dérivés. Cette substance est utilisée dans la préparation d'un médicament destiné au traitement de cancers.
PCT/EP2003/010280 2002-09-17 2003-09-16 Compositions pharmaceutiques utilisees pour le traitement de cancers WO2004026319A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003270202A AU2003270202A1 (en) 2002-09-17 2003-09-16 Pharmaceutical compositions increasing camp useful for the treatment of cancers

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41112002P 2002-09-17 2002-09-17
US60/411,120 2002-09-17

Publications (2)

Publication Number Publication Date
WO2004026319A2 WO2004026319A2 (fr) 2004-04-01
WO2004026319A3 true WO2004026319A3 (fr) 2004-09-02

Family

ID=32030650

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/010280 WO2004026319A2 (fr) 2002-09-17 2003-09-16 Compositions pharmaceutiques utilisees pour le traitement de cancers

Country Status (2)

Country Link
AU (1) AU2003270202A1 (fr)
WO (1) WO2004026319A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1838319B1 (fr) 2005-01-07 2018-03-07 The Johns Hopkins University Compositions d'inhibiteur des pde5 et procedes pour l'immunotherapie
EP2303255A1 (fr) * 2008-06-03 2011-04-06 Université Paris Diderot - Paris 7 Compositions pharmaceutiques utiles pour le traitement de cancers, en particulier d'une leucémie myéloïde aiguë et d'une leucémie promyélocytique aiguë
UA98666C2 (ru) * 2010-03-25 2012-06-11 Геннадий Васильевич Мазильников Лекарственный препарат на основе щавелевой кислоты, проявляющий противоопухолевое действие в отношении злокачественных клеток, и способ лечения
UA98665C2 (ru) * 2010-03-25 2012-06-11 Геннадий Васильевич Мазильников Лекарственный препарат, проявляющий противоопухолевое действие в отношении злокачественных клеток, и способ лечения
US9446064B2 (en) 2013-03-14 2016-09-20 Epizyme, Inc. Combination therapy for treating cancer
AU2014236348B2 (en) * 2013-03-14 2018-05-10 Epizyme, Inc. Combination therapy for treating cancer
US20150273088A1 (en) * 2014-03-28 2015-10-01 Washington University Zaprinast analogues as glutaminase inhibitors and methods to predict response thereto

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994004541A2 (fr) * 1992-08-12 1994-03-03 The Upjohn Company Inhibiteurs de proteine kinase et composes apparentes combines avec du taxol
US5880153A (en) * 1995-11-13 1999-03-09 Spinal Cord Society Method for upregulation of TRKB and TRKC receptors in central nervous system neurons
FR2782010A1 (fr) * 1998-08-06 2000-02-11 Inst Vaisseaux Et Du Sang Nouvelle utilisation d'un compose d'arsenic vis-a-vis de la leucemie megacaryocytaire ou plaquettaire
WO2000064260A1 (fr) * 1999-04-23 2000-11-02 Bristol-Myers Squibb Company Compositions et procedes pour traiter des maladies hyperproliferatives

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994004541A2 (fr) * 1992-08-12 1994-03-03 The Upjohn Company Inhibiteurs de proteine kinase et composes apparentes combines avec du taxol
US5880153A (en) * 1995-11-13 1999-03-09 Spinal Cord Society Method for upregulation of TRKB and TRKC receptors in central nervous system neurons
FR2782010A1 (fr) * 1998-08-06 2000-02-11 Inst Vaisseaux Et Du Sang Nouvelle utilisation d'un compose d'arsenic vis-a-vis de la leucemie megacaryocytaire ou plaquettaire
WO2000064260A1 (fr) * 1999-04-23 2000-11-02 Bristol-Myers Squibb Company Compositions et procedes pour traiter des maladies hyperproliferatives

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CHENG L ET AL: "CHARACTERISATIONS OF TAXOL-INDUCED APOPTOSIS AND ALTERED GENE EXPRESSION IN HUMAN BREAST CANCER CELLS", CELLULAR PHARMACOLOGY, STOCKTON PRESS, XX, vol. 2, no. 6, November 1995 (1995-11-01), pages 249 - 257, XP008013734, ISSN: 1351-3214 *
GUILLEMIN MARIE-CLAUDE ET AL: "In vivo activation of cAMP signaling induces growth arrest and differentiation in acute promyelocytic leukemia.", THE JOURNAL OF EXPERIMENTAL MEDICINE. UNITED STATES 18 NOV 2002, vol. 196, no. 10, 18 November 2002 (2002-11-18), pages 1373 - 1380, XP002267247, ISSN: 0022-1007 *
SRIVASTAVA R K ET AL: "Synergistic effects of 8-chlorocyclic-AMP and retinoic acid on induction of apoptosis in Ewing's sarcoma CHP-100 cells.", CLINICAL CANCER RESEARCH: AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. UNITED STATES MAR 1998, vol. 4, no. 3, March 1998 (1998-03-01), pages 755 - 761, XP001157237, ISSN: 1078-0432 *
SRIVASTAVA R K ET AL: "Synergistic effects of 8-Cl-cAMP and retinoic acids in the inhibition of growth and induction of apoptosis in ovarian cancer cells: induction of retinoic acid receptor beta.", MOLECULAR AND CELLULAR BIOCHEMISTRY. NETHERLANDS JAN 2000, vol. 204, no. 1-2, January 2000 (2000-01-01), pages 1 - 9, XP009024119, ISSN: 0300-8177 *
SRIVASTAVA R K ET AL: "Synergistic effects of retinoic acid and 8-Cl-cAMP on apoptosis require caspase-3 activation in human ovarian cancer cells.", ONCOGENE. ENGLAND 4 MAR 1999, vol. 18, no. 9, 4 March 1999 (1999-03-04), pages 1755 - 1763, XP002267248, ISSN: 0950-9232 *

Also Published As

Publication number Publication date
AU2003270202A1 (en) 2004-04-08
WO2004026319A2 (fr) 2004-04-01
AU2003270202A8 (en) 2004-04-08

Similar Documents

Publication Publication Date Title
WO2007146248A3 (fr) Préparations de laquinimod stables
TW200700406A (en) Novel thiophene derivatives
TW200716591A (en) Novel thiophene derivatives
TW200708511A (en) Novel thiophene derivatives
TW200716552A (en) Novel thiophene derivatives
WO2006086562A3 (fr) Derives de phenylazetidinone
TW200738670A (en) Novel thiophene derivatives
EP1521749B8 (fr) Derives de phenyl-(4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yl)-amine
IL168266A (en) Nucleoside derivatives, processes for their preparation. pharmaceutical compositions comprising them and uses thereof for the manufacture of medicaments
AU2003246810A1 (en) Diphenylpyridine derivatives, the preparation thereof, and pharmaceutical compositions containing said derivatives
WO2005086656A3 (fr) Derives d'heteroarylaminopyrazole utilises pour traiter le diabete
WO2006138735A3 (fr) Compositions de gel pour administration topique
MY154909A (en) Novel thiophene derivatives
IL164798A0 (en) Benzothiadiazepine derivatives, processes for their preparation and pharmaceutical compositions containing them
WO2006050161A3 (fr) Furopyrimidines et thienopyrimidines therapeutiques
IL163552A (en) Conjugates of biologically active compounds, uses thereof and pharmaceutical compositions comprising the same
WO2006131649A3 (fr) Utilisation de la fumagilline et de ses derives pour augmenter la biodisponibilite des lactones macrocycliques
ZA200403682B (en) N-adamantylmethyl derivatives and intermediates as pharmaceutical composition and processes for their preparation.
MY145074A (en) Thiazolidin-4-one derivatives
AU2003263599A1 (en) Pharmaceutical composition for topical delivery of meloxicam comprising an amine or amine as penetration enhancer.
WO2005117895A8 (fr) Compositions contenant de la meloxicame
WO2005009460A3 (fr) Composition pharmaceutique comportant l'activine a, l'alk-4 ou leurs derives pour le traitement des troubles ophtalmiques ou du cancer
ZA201003794B (en) Novel 1,3-dihydro-5-isobenzofurancarbonitrile derivatives and pharmaceutical composition thereof for the treatment of premature ejaculation
WO2005112923A3 (fr) Dérivés de 5-anilino-4-hétéroarylpyrazole utiles pour le traitement du diabete
WO2004026319A3 (fr) Compositions pharmaceutiques utilisees pour le traitement de cancers

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP